This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

SO282

The predictive value of C-reactive protein (CRP) for antidepressant treatment response in major depressive disorder

PREDICTIVE VALUE OF C-REACTIVE PROTEIN (CRP) FOR ANTIDEPRESSANT TREATMENT RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

Baseline CRP levels in major depressive disorder were not associated with response to escitalopram treatment, and the clinical utility of CRP as a biological predictor appeared limited.

The aim of the study was to evaluate whether baseline C-reactive protein (CRP) levels in major depressive disorder (MDD) were significantly associated with response to selective serotonin reuptake inhibitor (SSRI) treatment. Of 60 outpatients diagnosed with MDD according to DSM-5 criteria, 38 completed 8 weeks of escitalopram treatment; serum CRP was measured before medication initiation, depressive symptoms were assessed at baseline and week 8 using the 17-item Hamilton Depression Rating Scale (HAMD-17) and the Patient Health Questionnaire-9 (PHQ-9), and the association was examined using Pearson correlation and multivariable logistic regression. The mean age of the sample was 60.55 ± 15.16 years, the sex distribution was 15 men and 23 women, the mean daily escitalopram dose was 11.05 ± 4.37 mg, and the mean CRP level was 0.12 ± 0.12 mg/dL. Depressive symptoms improved significantly with treatment: PHQ-9 scores decreased from 14.74 ± 5.46 to 9.53 ± 5.38, and HAMD-17 scores decreased from 16.84 ± 3.73 to 12.08 ± 4.36 (p < 0.001 for both). No statistically significant correlations were found between baseline CRP levels and scale scores or changes in scores (baseline PHQ-9 r = 0.02, p = 0.912; baseline HAMD-17 r = -0.18, p = 0.275; change in PHQ-9 score r = 0.04, p = 0.795; change in HAMD-17 score r = -0.20, p = 0.239). When participants were classified as responders or nonresponders based on a reduction of 50% or more in depression scores after treatment, no significant correlations were found within the subgroups either. In multivariable logistic regression adjusted for age and sex, CRP did not predict treatment response (odds ratio (OR) for PHQ-9 response: 2.130, p = 0.791; OR for HAMD-17 response: 0.006, p = 0.341). In conclusion, the clinical utility of CRP as a biological predictor of SSRI response in MDD is limited; larger samples and multimodal biomarker-based prediction models are recommended for future studies.

All WCP 2026 summaries